Filtered By:
Cancer: Lung Cancer
Education: Academia
This page shows you your search results in order of date.
Order by Relevance | Date
Total 452 results found since Jan 2013.
Initial versus early switch to targeted therapy during first-line treatment among patients with biomarker-positive advanced or metastatic non-small cell lung cancer in the United States
CONCLUSION: In both unadjusted and adjusted analyses, there were no differences in the clinical outcomes observed among patients with a/mNSCLC in this study. This study found that initiating chemotherapy with an early switch to targeted therapy (within 56 days) of receiving biomarker positive results may be an acceptable strategy for a patient for whom immediate care is needed.PMID:37717466 | DOI:10.1016/j.ctarc.2023.100761
Source: Cell Research - September 17, 2023 Category: Cytology Authors: Lisa M Hess Patrick Peterson Tomoko Sugihara Naleen Raj Bhandari Peter M Krein Anthony Sireci Source Type: research
Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy
CONCLUSIONS: Early treatment period CRP and LDH levels were significant predictors of OS in patients with NSCLC undergoing immunotherapy.PMID:37577328 | PMC:PMC10413036 | DOI:10.21037/tlcr-23-7
Source: Cell Research - August 14, 2023 Category: Cytology Authors: MinDong Sung Won Seok Jang Hae Reong Kim Ji Ae Park Sun Min Lim Hye Ryun Kim Byoung Chul Cho Yu Rang Park Min Hee Hong Source Type: research
The success rates of clinical cancer next-generation sequencing based on pathologic diagnosis: Experience from a single academic laboratory
CONCLUSIONS: The success rate of cancer next-generation sequencing testing is dependent on pathologic diagnosis, tissue site, and diagnostic procedure. Understanding which specimens are at higher risk for failing molecular testing may help pathologists and clinical care teams optimize tissue acquisition and usage for patient care.PMID:37543867 | DOI:10.1093/ajcp/aqad092
Source: Clinical Lung Cancer - August 6, 2023 Category: Cancer & Oncology Authors: Katherine Latham Fei Dong Source Type: research
Is Sarcomatoid Lung Cancer Associated With Inferior Overall Survival? A National Cancer Database Analysis
CONCLUSIONS: This National Cancer Database study confirms the findings of smaller studies that sarcomatoid cancer is associated with inferior overall survival compared to other NSCLCs. Given the inferior prognosis, further studies regarding optimal staging practices are appropriate.PMID:37516045 | DOI:10.1016/j.jss.2023.06.027
Source: Cell Research - July 29, 2023 Category: Cytology Authors: Lauren M Poston Aria Bassiri Boxiang Jiang Christina Boutros Jillian Sinopoli Leonidas Tapias Vargas Philip A Linden Christopher W Towe Source Type: research
Factors associated with lung cancer risk factor documentation
CONCLUSIONS: We found a low rate of sufficient lung cancer risk factor documentation and associations of risk factor documentation based on patient-level factors such as race, insurance status, language, and patient portal activation. Risk factor documentation rates varied across clinics, and only approximately half the variation was explained by factors in our analysis.PMID:37428463
Source: The American Journal of Managed Care - July 10, 2023 Category: Health Management Authors: Leah M Marcotte Sara Khor David R Flum Nkem Akinsoto Vandna Chaudhari Douglas E Wood Danielle C Lavallee Matthew Triplette Farhood Farjah Source Type: research
Patient-led advocacy in ALK-positive lung cancer
Transl Lung Cancer Res. 2023 Jun 30;12(6):1303-1319. doi: 10.21037/tlcr-22-713. Epub 2023 Jun 29.ABSTRACTPatient-led advocacy organizations in the anaplastic lymphoma kinase (ALK)-positive lung cancer space are becoming increasingly influential. ALK Positive Inc. (hereafter "ALK Positive") is probably the most widely known among these organizations. Evolving from a private Facebook Support Group created in 2015 to provide a forum for ALK-positive lung cancer patients and caregivers to exchange information, empathy and support, ALK Positive transitioned in 2021 into a 501(c)(3) non-profit organization (NPO), with the missio...
Source: Cell Research - July 10, 2023 Category: Cytology Authors: Colin Barton Morhaf Al Achkar Jennifer A Blender Summer Hall Farmen Raymond B Hall Afroditi Maria Konidari Debbi Martinez Nancee Pronsati Marc Rosenzweig Carla Vass Emily S Venanzi William Westlake Marc A T Muskavitch Source Type: research
Factors associated with lung cancer risk factor documentation
Conclusions: We found a low rate of sufficient lung cancer risk factor documentation and associations of risk factor documentation based on patient-level factors such as race, insurance status, language, and patient portal activation. Risk factor documentation rates varied across clinics, and only approximately half the variation was explained by factors in our analysis.PMID:37428463
Source: The American Journal of Managed Care - July 10, 2023 Category: Health Management Authors: Leah M Marcotte Sara Khor David R Flum Nkem Akinsoto Vandna Chaudhari Douglas E Wood Danielle C Lavallee Matthew Triplette Farhood Farjah Source Type: research
Stratification of Risk Factors of Lung Cancer-Associated Venous Thromboembolism and Determining the Critical Point for Preemptive Intervention: A Systematic Review With Meta-analysis
CONCLUSIONS: Targeted screening for VTE in lung cancer patients could be patient-specific and should be based on a combination of the most significant risk factors required to meet the critical point, provided that such a combination is affordable as illustrated in the ALBAH model.REGISTRATION: The review protocol is registered with PROSPERO (ID: CRD42022336476).PMID:37426681 | PMC:PMC10328178 | DOI:10.1177/11795549231175221
Source: Clinical Lung Cancer - July 10, 2023 Category: Cancer & Oncology Authors: Theresa Nwagha Martins Nweke Source Type: research
Infectious Complications in Patients With Non-small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
CONCLUSION: In this large single-institution study we identify that more than half of patients with ICI-treated NSCLC develop infectious complications. We identify that patients with COPD, recent corticosteroid use, and concomitant irAE and infection have higher odds of hospitalization, and that unusual infections (eg, fungal) can occur. This highlights clinical awareness of infections as important complications during ICI therapy in patients with NSCLC.PMID:37419702 | DOI:10.1016/j.cllc.2023.06.011
Source: Clinical Lung Cancer - July 7, 2023 Category: Cancer & Oncology Authors: Matthew Z Guo Aanika Balaji Joseph C Murray Joshua E Reuss Seema Mehta Steinke Kathleen Bennett Jarushka Naidoo Source Type: research
Adapting the Evidence Academy model for virtual stakeholder engagement in a national setting during the COVID-19 pandemic
J Clin Transl Sci. 2023 Mar 20;7(1):e98. doi: 10.1017/cts.2023.37. eCollection 2023.ABSTRACTThe COVID-19 pandemic raised the importance of adaptive capacity and preparedness when engaging historically marginalized populations in research and practice. The Rapid Acceleration of Diagnostics in Underserved Populations' COVID-19 Equity Evidence Academy Series (RADx-UP EA) is a virtual, national, interactive conference model designed to support and engage community-academic partnerships in a collaborative effort to improve practices that overcome disparities in SARS-CoV-2 testing and testing technologies. The RADx-UP EA promote...
Source: Clinical Lung Cancer - May 30, 2023 Category: Cancer & Oncology Authors: Lori Carter-Edwards Renee Leverty Alicia Bilheimer Lindsay Bailey Bukola Adeshina Prabisha Shrestha Zhitong Yu Gaurav Dave Michael Cohen-Wolkowiez Warren Kibbe Giselle Corbie Source Type: research
Rationale and value of consolidative cranial local therapy in EGFR-mutant non-small cell lung cancer patients with baseline brain metastasis treated with first-line EGFR-TKIs
CONCLUSIONS: Cranial progressive disease developed mostly at the residual cranial lesions in EGFR-mutant NSCLC patients with baseline BMs who received first-line EGFR-TKIs. Consolidative cranial local therapy targeting the oligo-residual cranial tumor lesions may provide survival benefit, which warrants future validation.PMID:37152422 | PMC:PMC10161332 | DOI:10.1177/17588359231169975
Source: Adv Data - May 8, 2023 Category: Epidemiology Authors: Ya Zeng Xi Su Yang Zhao Yue Zhou Tiantian Guo Xiao Chu Li Chu Xi Yang Jianjiao Ni Zhengfei Zhu Source Type: research
Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis
CONCLUSIONS: Treatment regimens that combine ICIs before, concurrent with, and after SBRT for spine metastases are safe, with minimal risk for increased rates of long-term toxicity.PMID:37148233 | DOI:10.3171/2023.3.SPINE221086
Source: Journal of Neurosurgery.Spine - May 6, 2023 Category: Neurosurgery Authors: Emerson Lee Xuguang Chen Michael C LeCompte Lawrence R Kleinberg Russell K Hales Khinh Ranh Voong Patrick M Forde Julie R Brahmer Mark C Markowski Evan J Lipson Sang Hun Lee Ali Bydon Sheng-Fu Larry Lo Daniel Lubelski Kristin J Redmond Source Type: research
